A case report from Türkiye described sustained CNS remission in heavily pre-treated multiple myeloma after a BCMA-targeted bispecific antibody combined with intrathecal chemotherapy. The report, published in the clinical literature, highlights the potential role of CNS-directed combination strategies for patients with central nervous system involvement. In an additional oncology mechanism focus, Adelaide University researchers reported an mRNA-based approach that reprograms tumor defenses to enhance immune attack, published in Science Advances. The work positions mRNA therapeutics as a way to modulate the tumor microenvironment rather than solely deliver antigens. Together, the items reflect intensifying interest in immune orchestration and CNS coverage strategies across difficult patient subgroups.